![Axplora expands ADC capacity, Merck KGaA CDMO business slump, FDA issues a warning letter to Granules India [The good, the bad, the ugly] episode artwork](https://pbcdn1.podbean.com/imglogo/image-logo/9655061/Security_14__hjvhxj.jpg){kind=logo}
EPISODE · Mar 17, 2025 · 3 MIN
Axplora expands ADC capacity, Merck KGaA CDMO business slump, FDA issues a warning letter to Granules India [The good, the bad, the ugly]
from Off Script: A Pharma Manufacturing Podcast · host Pharma Manufacturing
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad, and one ugly. Up this week: The good — Axplora expands its antibody-drug conjugate (ADC) manufacturing capacity to support growing demand. The bad — Merck KGaA’s CDMO business reports a decline The ugly — The FDA issues a warning letter to Granules India over manufacturing violations
Embed this episode
NOW PLAYING
Axplora expands ADC capacity, Merck KGaA CDMO business slump, FDA issues a warning letter to Granules India [The good, the bad, the ugly]
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.